To Evaluate the Effect of MCS® in Prostate Cancer Prevention
Phase 2
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: PlaceboDrug: MCS®
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 702
- Registration Number
- NCT02042807
- Locations
- 🇨🇳
Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia
Phase 2
Terminated
- Conditions
- Male Oligoasthenospermia
- Interventions
- Drug: MCS
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT01016340
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Pharmacokinetics of MCS in Healthy Volunteers
Phase 1
- Conditions
- Healthy
- Interventions
- Drug: MCS-2 soft-gel capsule
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01003171
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
Phase 3
Completed
- Conditions
- Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT01002274
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
MCS in the Treatment of Lower Urinary Tract Symptoms
Phase 2
Completed
- Conditions
- Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia
- Interventions
- Drug: MCS-2 15 mg/dayDrug: PlaceboDrug: MCS-2 30 mg/day
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 274
- Registration Number
- NCT01002417
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
Phase 3
Completed
- Conditions
- Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT01002222
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
Phase 3
Completed
- Conditions
- Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT01002664
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia
Phase 3
Terminated
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: MCSDrug: Placebo
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2011-12-14
- Lead Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT00501371
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Chiayi, Taiwan
🇨🇳Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
🇨🇳Chung-Ho Memorial Hospital,Kaohsiung Medical University, Kaohsiung, Taiwan
© Copyright 2025. All Rights Reserved by MedPath